Editas Medicine Inc (EDIT) Sees Large Increase in Short Interest

Editas Medicine Inc (NASDAQ:EDIT) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 6,779,942 shares, a growth of 30.1% from the January 15th total of 5,212,649 shares. Based on an average daily trading volume, of 1,560,927 shares, the short-interest ratio is currently 4.3 days. Currently, 14.8% of the shares of the company are short sold.

EDIT stock traded up $0.22 during mid-day trading on Monday, reaching $19.97. 531,083 shares of the stock traded hands, compared to its average volume of 1,148,200. The firm has a market capitalization of $944.25 million, a PE ratio of -6.70 and a beta of 2.56. Editas Medicine has a 52-week low of $17.80 and a 52-week high of $45.02. The company has a current ratio of 13.14, a quick ratio of 13.13 and a debt-to-equity ratio of 0.15.

In other Editas Medicine news, insider Vickesh Myer sold 7,000 shares of the business’s stock in a transaction dated Tuesday, December 18th. The shares were sold at an average price of $27.61, for a total value of $193,270.00. Following the transaction, the insider now directly owns 3,000 shares in the company, valued at approximately $82,830. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew A. F. Hack sold 5,284 shares of the company’s stock in a transaction that occurred on Friday, November 23rd. The stock was sold at an average price of $28.15, for a total transaction of $148,744.60. Following the completion of the transaction, the chief financial officer now owns 5,284 shares in the company, valued at $148,744.60. The disclosure for this sale can be found here. Insiders sold 61,179 shares of company stock valued at $1,623,659 in the last ninety days. 5.20% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in EDIT. We Are One Seven LLC bought a new stake in Editas Medicine during the fourth quarter worth approximately $40,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Editas Medicine by 34.2% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,160 shares of the company’s stock worth $113,000 after acquiring an additional 1,314 shares in the last quarter. Ancora Advisors LLC acquired a new position in Editas Medicine during the third quarter worth $127,000. TRUE Private Wealth Advisors acquired a new position in Editas Medicine during the third quarter worth $137,000. Finally, Edge Wealth Management LLC acquired a new stake in shares of Editas Medicine in the fourth quarter valued at $160,000. Hedge funds and other institutional investors own 69.12% of the company’s stock.

A number of research firms recently commented on EDIT. BTIG Research began coverage on shares of Editas Medicine in a research report on Thursday. They issued a “buy” rating and a $30.00 target price on the stock. ValuEngine cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Zacks Investment Research cut shares of Editas Medicine from a “buy” rating to a “hold” rating in a research note on Friday, February 1st. BidaskClub cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Finally, JPMorgan Chase & Co. restated a “hold” rating on shares of Editas Medicine in a report on Tuesday, January 22nd. Three analysts have rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $42.50.

COPYRIGHT VIOLATION WARNING: “Editas Medicine Inc (EDIT) Sees Large Increase in Short Interest” was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.thestockobserver.com/2019/02/11/editas-medicine-inc-edit-sees-large-increase-in-short-interest.html.

Editas Medicine Company Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

See Also: Fundamental Analysis and Choosing Stocks

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply